San Diego biotech eFFECTOR Therapeutics to go public via SPAC merger
EFFECTOR would be the second San Diego firm to go public this year in a SPAC deal, joining electric vehicle-to-grid firm Nuvve.
Stay updated with breaking news from Chris Ehrlich. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
EFFECTOR would be the second San Diego firm to go public this year in a SPAC deal, joining electric vehicle-to-grid firm Nuvve.
by Kyle LaHucik | May 27, 2021 10:50am EFFECTOR Therapeutics will hit the stock market by merging with blank check company Locust Walk Acquisition. (Getty Images) In a sign of the SPAC times, eFFECTOR Therapeutics was one of a whopping 90-plus biotech assets to be scouted by just one blank check company. The clinical-stage biotech, which is focused on selective translation regulation inhibitors (STRIs) in cancer, ended up persevering in the battle to go public. EFFECTOR and Locust Walk Acquisition Corp. today announced their merger deal, coming ami...
A biotechnology company using selective tranlsation regulation inhibitors to treat cancer is going public in a SPAC deal. The SPAC Deal: eFFECTOR ...
Gross proceeds expected to include $60 million from a committed PIPE and up to $175 million held in trust Anticipated cash resources will fund eFFECTOR's ...
Alexander Thompson / somerville@wickedlocal.com Both city development officials and the urban planning consultants working with them made one thing clear during a community meeting about the development of Gilman Square on March 10: They want to put the square back in Gilman Square. At the meeting, urban planners and architects from the firm BBNJ laid out six possible layouts for the square, but said that nothing has been decided and that they are still looking for community input. The development area includes the site of the old Homans Building, the Mobile gas station and the area in front ...